1383570-60-2

Upstream product

• 1383570-15-7 tert-butyl [(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl]carbamate 
• 1383570-59-9 tert-butyl [(2R,5R)-5-amino-1,6-diphenylhexan-2-yl]carbamate 
• 1383570-58-8 (S)-N-((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamide hydrochloride 
• 1401248-97-2 tert-butyl 5-(((4-nitrophenoxy)carbonyloxy)methyl)-1H-imidazole-1-carboxylate 

Downstream Products

• 1383570-21-5 (1H-imidazol-5-yl)methyl [(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl]carbamate 

Relevant academic research and scientific papers

Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir

Utilization of the cytochrome P450 3A4 (CYP3A4) inhibitor ritonavir as a pharmacoenhancer for anti-HIV drugs revolutionized the treatment of HIV infection. However, owing to ritonavir-related complications, there is a need for development of new CYP3A4 in

INHIBITORS OF CYTOCHROME P450 (CYP3A4)

The present application provides for a compound of formula I, and related compounds, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional therapeutic agent.